Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vicals VaxfectinR Adjuvant – MarketWatchPosted: March 28, 2012
The mouse-generated Pvs230 antibodies, incubated with P. vivax-infected human red blood cells and then fed to mosquitoes, statistically reduced the number of parasites and the infection rate in mosquitoes. A VaxfectinR-formulated malaria vaccine therefore has the potential to interfere with the transmission of P. vivax to humans through mosquitoes. This novel transmission-blocking approach may thereby protect the broader population from widespread malaria outbreaks. Further study of the vaccine candidate has been proposed by the authors.